Abstract: The present invention features solid pharmaceutical compositions comprising Compound 1 and Compound 2. In one embodiment, the solid pharmaceutical composition includes (1) a first layer which comprises 100 mg Compound 1, as well as a pharmaceutically acceptable hydrophilic polymer and a pharmaceutically acceptable surfactant, all of which are formulated in amorphous solid dispersion; and (2) a second layer which comprises 40 mg Compound 2, as well as a pharmaceutically acceptable hydrophilic polymer and a pharmaceutically acceptable surfactant, all of which are formulated in amorphous solid dispersion.

Abstract: The invention relates to pharmaceutical formulations comprising an active pharmaceutical ingredient; and one of or a combination of methacrylic acid copolymer, or a cellulose derivative wherein the active pharmaceutical ingredient is a dengue viral replication inhibitor. Solid dosage forms comprising said pharmaceutical formulations, processes for preparing these and their use in methods of prevention and/or treatment and/or inhibition of viral replication are also described.

Abstract: Described herein are pharmaceutical formulations comprising a MALT1 inhibitor and a mixture comprising fatty acid and polyethylene glycol monoesters and diesters, and optionally, fatty acid and glycerol monoesters, diesters and triesters. Solid dosage forms comprising said pharmaceutical formulations, processes for preparing these and their use in methods of treatment are also described.

Abstract: The invention relates to pharmaceutical formulations comprising an active pharmaceutical ingredient, glyceryl palmitostearate, and D-?-tocopherol polyethylene glycol succinate (TPGS). Solid dosage forms comprising said pharmaceutical formulations, processes for preparing these and their use in methods of treatment are also described.

Abstract: A system and method for recognizing traffic signs during autonomous driving comprises a camera module obtaining a first recognition, a sensor obtains behavior information of the host vehicle and of nearby vehicles and a connected training module generates parameters for traffic sign recognition according to information as to the behavior of the host vehicle and the nearby vehicles. A recurrent neural network module is connected with the training module and the camera module, and outputs a second traffic sign recognition according to the parameters and the first recognition. Training parameters of the second recognition comprise the traffic sign recognition parameters and the first recognition, the accuracy of the training result being improved by combining other sensors to perform traffic sign recognition training.

Abstract: The present invention features solid pharmaceutical compositions comprising Compound 1 and Compound 2. In one embodiment, the solid pharmaceutical composition includes (1) a first layer which comprises 100 mg Compound 1, as well as a pharmaceutically acceptable hydrophilic polymer and a pharmaceutically acceptable surfactant, all of which are formulated in amorphous solid dispersion; and (2) a second layer which comprises 40 mg Compound 2, as well as a pharmaceutically acceptable hydrophilic polymer and a pharmaceutically acceptable surfactant, all of which are formulated in amorphous solid dispersion.

Abstract: The present invention features solid pharmaceutical compositions comprising Compound 1 and Compound 2. In one embodiment, the solid pharmaceutical composition includes (1) a first layer which comprises 100 mg Compound 1, as well as a pharmaceutically acceptable hydrophilic polymer and a pharmaceutically acceptable surfactant, all of which are formulated in amorphous solid dispersion; and (2) a second layer which comprises 40 mg Compound 2, as well as a pharmaceutically acceptable hydrophilic polymer and a pharmaceutically acceptable surfactant, all of which are formulated in amorphous solid dispersion.

Abstract: The present invention features solid pharmaceutical compositions comprising Compound 1 and Compound 2. In one embodiment, the solid pharmaceutical composition includes (1) a first layer which comprises 100 mg Compound 1, as well as a pharmaceutically acceptable hydrophilic polymer and a pharmaceutically acceptable surfactant, all of which are formulated in amorphous solid dispersion; and (2) a second layer which comprises 40 mg Compound 2, as well as a pharmaceutically acceptable hydrophilic polymer and a pharmaceutically acceptable surfactant, all of which are formulated in amorphous solid dispersion.

Abstract: The present invention features solid pharmaceutical compositions comprising Compound 1 and Compound 2. In one embodiment, the solid pharmaceutical composition includes (1) a first layer which comprises 100 mg Compound 1, as well as a pharmaceutically acceptable hydrophilic polymer and a pharmaceutically acceptable surfactant, all of which are formulated in amorphous solid dispersion; and (2) a second layer which comprises 40 mg Compound 2, as well as a pharmaceutically acceptable hydrophilic polymer and a pharmaceutically acceptable surfactant, all of which are formulated in amorphous solid dispersion.

Abstract: The present invention features crystalline polymorphs of dimethyl (2S,2?S)-1,1,-((2S,2?S)-2,2,-(4,4,-((2S,5S)-1-(4-tert-butylphenyl) pyrrolidine-2,5-diyl) bis (4,1-phenylene)) bis (azanediyl) bis (oxomethylene) bis (pyrrolidine-2,1-diyl)) bis (3-methyl-1-oxobutane-2,1-diyl) dicarbamate i.e. ombitasvir, compound (I), which is a potent HCV NS5A inhibitor. In one embodiment, a crystalline form of Compound (I) has characteristic peaks in the PXRD pattern as shown in one of FIGS. 1-11.

Abstract: The present invention relates to a control circuitry module group, an electrical device, and a modem device. The control circuitry module group is configured for communication and/or power supply between a master control module and at least one slave modules in an electrical device. The control circuitry module group comprises: a bus; a bus control module coupled to the master control module and the bus, configured to receive a control signal from the master control module, add a target address in the control signal, and send to the bus the control signal with the target address; and at least one slave control modules each coupled to a corresponding slave module and the bus, respectively, and configured to receive the control signal with the target address via the bus, and controlling power supply to the slave module in response to the control signal.

Abstract: The present invention features solid pharmaceutical compositions comprising Compound 1 and Compound 2. In one embodiment, the solid pharmaceutical composition includes (1) a first layer which comprises 100 mg Compound 1, as well as a pharmaceutically acceptable hydrophilic polymer and a pharmaceutically acceptable surfactant, all of which are formulated in amorphous solid dispersion; and (2) a second layer which comprises 40 mg Compound 2, as well as a pharmaceutically acceptable hydrophilic polymer and a pharmaceutically acceptable surfactant, all of which are formulated in amorphous solid dispersion.

Abstract: The present invention features solid pharmaceutical compositions comprising Compound 1 and Compound 2. In one embodiment, the solid pharmaceutical composition includes (1) a first layer which comprises 100 mg Compound 1, as well as a pharmaceutically acceptable hydrophilic polymer and a pharmaceutically acceptable surfactant, all of which are formulated in amorphous solid dispersion; and (2) a second layer which comprises 40 mg Compound 2, as well as a pharmaceutically acceptable hydrophilic polymer and a pharmaceutically acceptable surfactant, all of which are formulated in amorphous solid dispersion.

Abstract: The present invention features crystalline forms of Compound I.

Abstract: The present invention relates to a control circuitry module group, an electrical device, and a modem device. The control circuitry module group is configured for communication and/or power supply between a master control module and at least one slave modules in an electrical device. The control circuitry module group comprises: a bus; a bus control module coupled to the master control module and the bus, configured to receive a control signal from the master control module, add a target address in the control signal, and send to the bus the control signal with the target address; and at least one slave control modules each coupled to a corresponding slave module and the bus, respectively, and configured to receive the control signal with the target address via the bus, and controlling power supply to the slave module in response to the control signal.